Stockscreener 앱 받기
4.02
3.08%
0.12
시장 영업 전:
3.94
-0.08
-1.99%
전일 마감가:
$3.90
열려 있는:
$3.95
하루 거래량:
4.36M
Relative Volume:
0.92
시가총액:
$604.49M
수익:
$4.21M
순이익/손실:
$-97.67M
주가수익비율:
-4.3226
EPS:
-0.93
순현금흐름:
$-70.76M
1주 성능:
+15.19%
1개월 성능:
+12.29%
6개월 성능:
+55.81%
1년 성능:
+30.94%
1일 변동 폭
$3.94
$4.155
1주일 범위
$3.49
$4.155
52주 변동 폭
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
명칭
Absci Corp
전화
(360) 949-1041
주소
18105 SE MILL PLAIN BLVD, VANCOUVER
ABSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
4.02 | 586.45M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-02 | 개시 | JP Morgan | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-01-22 | 개시 | Needham | Buy |
| 2024-10-02 | 개시 | Guggenheim | Buy |
| 2024-07-03 | 개시 | Morgan Stanley | Overweight |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | 개시 | H.C. Wainwright | Buy |
| 2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-07-18 | 개시 | Truist | Buy |
| 2022-03-02 | 재개 | Cowen | Market Perform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-11-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-08-16 | 개시 | BofA Securities | Neutral |
| 2021-08-16 | 개시 | Cowen | Market Perform |
| 2021-08-16 | 개시 | Credit Suisse | Outperform |
| 2021-08-16 | 개시 | Stifel | Hold |
모두보기
Absci Corp 주식(ABSI)의 최신 뉴스
Morgan Stanley downgrades Absci stock on TL1A setback and higher risk profile - Investing.com UK
How resilient is Absci Corporation stock in market downturnsEarnings Miss & AI Optimized Trade Strategies - moha.gov.vn
Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Absci Unveils Preclinical Data for AI-Designed ABS-201, Targeting a Novel Hormonal Pathway for Hair Loss Treatment - Finviz
Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial - Finviz
Morgan Stanley Assumes Coverage on Absci Corporation (ABSI) with $7 Target - MSN
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential - Finviz
Absci (NASDAQ:ABSI) Trading Down 4.2%Here's What Happened - MarketBeat
Absci (NASDAQ:ABSI) Trading Up 11.1%Time to Buy? - MarketBeat
Why analysts remain bullish on Absci Corporation stockWeekly Profit Analysis & Smart Investment Allocation Tips - Улправда
Will Absci Corporation stock recover faster than peersMarket Risk Summary & Reliable Entry Point Alerts - Улправда
What technical charts say about Absci Corporation stock2025 Pullback Review & Weekly Chart Analysis and Trade Guides - Улправда
Is Absci Corporation stock a defensive play in 2025CPI Data & Risk Controlled Stock Pick Alerts - Улправда
Will Absci Corporation stock keep outperforming rivalsPortfolio Update Summary & Weekly Sector Rotation Insights - Улправда
ABSI Stock: HC Wainwright & Co. Raises Price Target to $8.00 | A - GuruFocus
Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside - Insider Monkey
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $8 - 富途牛牛
14 Best Multibagger Penny Stocks to Buy Right Now - Insider Monkey
Will ABS-201 From Absci Transform The Future Of Hair Regeneration? - RTTNews
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci’s ABS-201 stimulates human hair follicle growth ex vivo - BioWorld MedTech
Independent Director of Absci Picks Up 454% More Stock - Yahoo Finance
Absci, former US soccer player Donovan announce partnership - MSN
Absci’s ABS-201 antibody shows promise for hair regrowth treatment - Investing.com
Absci’s ABS-201 antibody shows promise for hair regrowth treatment By Investing.com - Investing.com Canada
Absci Reports New Human Ex Vivo Data Demonstrating That - GlobeNewswire
Is Absci Poised for a Surge? - StocksToTrade
Absci (NASDAQ:ABSI) Shares Gap UpShould You Buy? - MarketBeat
Absci, former U.S. soccer player Donovan announce partnership - TipRanks
Absci Corporation Partners with Landon Donovan to Address Androgenetic Alopecia and Advance Therapeutic Innovations - Quiver Quantitative
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewswire
Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration - Kalkine Media
Absci Corp Director Frans Van Houten Acquires 40,000 Shares - TradingView — Track All Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Dir Van Houten Buys 40,000 ($148.8K) Of AbSci Corp [ABSI] - TradingView — Track All Markets
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail
Absci (NASDAQ:ABSI) Stock Price Up 10.8%Still a Buy? - MarketBeat
Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Nigeria
Absci doses first volunteers in phase 1/2a trial of hair loss antibody By Investing.com - Investing.com South Africa
Absci Stock’s Financial Prospects: An In-Depth Analysis - StocksToTrade
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com
Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance
Absci Corp (ABSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):